The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries

@article{Gleeson2018TheTP,
  title={The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries},
  author={Deborah Gleeson and Joel Lexchin and Ruth Lopert and Burcu İşg{\"u}den Kılıç},
  journal={Global Social Policy},
  year={2018},
  volume={18},
  pages={7 - 27}
}
The final text of the Trans Pacific Partnership Agreement (TPP), agreed between the 12 negotiating countries in 2016, included a suite of intellectual property provisions intended to expand and extend pharmaceutical company exclusivities on medicines. It drew wide criticism for including such provisions in an agreement that involved developing countries (Vietnam, Peru, Malaysia, Mexico, Chile and Brunei Darussalam) because of the effect on delaying the introduction of low-cost generics. While… Expand
Assessing Access to Medicines in Preferential Trade Agreements: From the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership
The Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP or TPP11) is a trade agreement between Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, NewExpand
Assessing Access to Medicines in Preferential Trade Agreements: From the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership
The Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP or TPP11) is a trade agreement between Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, NewExpand
The Trans-Pacific Partnership’s patent linkage: Unfriending or befriending the right to biologics?
The World Trade Organization brought Intellectual Property Rights into the multilateral trading system. The adoption of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS),Expand
Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States
TLDR
Where countries accept treaty obligations to establish patent linkage mechanisms, the impact on access to generic medicines may be moderated to a degree by retaining and exploiting constructive ambiguities in the treaty text and addressing practical aspects of implementation. Expand
Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
TLDR
A framework exploring the ways in which trade and investment agreements may affect pharmaceutical policy was developed, based on an analysis of four recently negotiated regional trade agreements, linking ten types of provisions in the four trade agreements to potential impacts on four core pharmaceutical policy objectives via various pathways. Expand
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
TLDR
The collective impact of these policy changes will be to extend the regulatory protection period for new drugs from an average of 10.0 years to 11.1 years, which may further assist in budget planning to mitigate increased cost to the downstream health authorities most impacted by these trade concessions. Expand
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
TLDR
An interdisciplinary review of the patent status of EML cancer medicines compared to other EML noncommunicable disease medicines using the 17th, 18th, 19th, 20th, and 21st editions of the list concludes that patent status is simply one factor in the complex international environment of health systems, IPR policies, and trade regimes. Expand
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
  • K. Son
  • Business, Medicine
  • Globalization and Health
  • 2020
TLDR
Recently signed international agreements favor companies over governments with underscoring procedural fairness and timely access, however, access to affordable medicines is the goal towards which international agreements should aim. Expand
What Generates Attention to Health in Trade PolicyMaking? Lessons From Success in Tobacco Control and Access to Medicines: A Qualitative Study of Australia and the (Comprehensive and Progressive) Trans-Pacific Partnership.
TLDR
Analysis of Australia's participation in the Trans-Pacific Partnership negotiations and the domestic agenda-setting processes that shaped the government's negotiating mandate provides insights for potential pathways to elevate greater attention to health in future. Expand
Glossary on free trade agreements and health part 2: new trade rules and new urgencies in the context of COVID-19
TLDR
Following a broader discussion of how the current political context and the COVID-19 pandemic shape the contemporary trade environment, part 2 of the glossary considers the main areas of trade and health policy incoherence as well as recommendations to address them. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 76 REFERENCES
The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines.
After a difficult legislative battle, President Obama signed into law Trade Promotion Authority on June 29, 2015. The legislation allows for an up-or-down vote with no amendments in Congress forExpand
The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia
  • J. Lexchin, D. Gleeson
  • Economics, Medicine
  • International journal of health services : planning, administration, evaluation
  • 2016
TLDR
The article concludes that the TPP could have profound effects on the criteria these countries use to decide on drug safety and effectiveness, how new drugs are approved (or not) for marketing, post-market surveillance and inspection, the listing of drugs on public formularies, and how individual drugs are priced in the future. Expand
The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam
TLDR
Results indicate that at current funding levels 82% of Vietnam’s eligible people living with HIV would receive ARVs if legal flexibilities were fully utilised, while as few as 30% may have access to ARVs under the TPP Agreement – more than halving the proportion currently treated. Expand
Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans‐Pacific Partnership Agreement
TLDR
Three of the greatest concerns for Australia in the recent draft include provisions that would further entrench secondary patenting and evergreening, lock in extensions to patent terms and extend monopoly rights over clinical trial data for certain medicines. Expand
Four Lessons for Developing Countries from the Trade Negotiations Over Access to Medicines
After the Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into operation in 1995 developing countries have found themselves in a process of continual negotiationExpand
CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
TLDR
This analysis estimates that CETA’s provisions will increase Canadian drug costs by between 6.2% and 12.9% starting in 2023 and negatively impact the ability of Canada to offer quality health care. Expand
The High Price of “Free” Trade: U.S. Trade Agreements and Access to Medicines
TLDR
The pursuit of increasing levels of intellectual property protection in successive bilateral and regional trade agreements has been driven, at least in part, by a U.S. desire to achieve standards of protection it anticipated from the TRIPS Agreement, but failed to secure. Expand
The Trans-Pacific Partnership: Is it Everything We Feared for Health?
TLDR
The analysis shows that there are a number of potentially serious health risks associated with the TPP, and details a range of policy implications for the health sector, and suggests that broad public consultations, including on the health risks of trade and investment agreements, should be part of all trade negotiations. Expand
All Costs, No Benefits: How TRIPS plus intellectual property rules in the US-Jordan FTA affect access to medicines
The USA continues to impose TRIPS-plus rules on developing countries, thus preventing poor people from accessing inexpensive, generic medicines. Jordan was required under the terms of its WTOExpand
Trade, TRIPS, and pharmaceuticals
TLDR
The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus. Expand
...
1
2
3
4
5
...